GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paragon 28 Inc (NYSE:FNA) » Definitions » Cash Flow from Financing

Paragon 28 (Paragon 28) Cash Flow from Financing : $128.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Paragon 28 Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Paragon 28 paid $0.0 Mil more to buy back shares than it received from issuing new shares. It received $69.8 Mil from issuing more debt. It paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.0 Mil from paying cash dividends to shareholders. It spent $6.7 Mil on other financial activities. In all, Paragon 28 earned $63.2 Mil on financial activities for the three months ended in Dec. 2023.


Paragon 28 Cash Flow from Financing Historical Data

The historical data trend for Paragon 28's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paragon 28 Cash Flow from Financing Chart

Paragon 28 Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
6.55 24.01 131.10 39.49 128.65

Paragon 28 Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 69.37 -2.54 -1.35 63.17

Paragon 28 Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Paragon 28's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Paragon 28's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $128.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paragon 28  (NYSE:FNA) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Paragon 28's issuance of stock for the three months ended in Dec. 2023 was $0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Paragon 28's repurchase of stock for the three months ended in Dec. 2023 was $0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Paragon 28's net issuance of debt for the three months ended in Dec. 2023 was $69.8 Mil. Paragon 28 received $69.8 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Paragon 28's net issuance of preferred for the three months ended in Dec. 2023 was $0.0 Mil. Paragon 28 paid $0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Paragon 28's cash flow for dividends for the three months ended in Dec. 2023 was $0.0 Mil. Paragon 28 received $0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Paragon 28's other financing for the three months ended in Dec. 2023 was $-6.7 Mil. Paragon 28 spent $6.7 Mil on other financial activities.


Paragon 28 Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Paragon 28's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Paragon 28 (Paragon 28) Business Description

Traded in Other Exchanges
Address
14445 Grasslands Drive, Englewood, CO, USA, 80112
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.
Executives
Albert Dacosta director, officer: See Remarks C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Robert S Mccormack officer: See Remarks C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Kristina Wright director C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
B. Ag Bird 10 percent owner BAHNHOFSTRASSE 7, ZUG V8 CH-6300
Mvm Partners, Llc 10 percent owner OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Matthew Jarboe officer: Chief Commercial Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Partners Llp Mvm 10 percent owner 30 ST. GEORGE STREET, LONDON X0 W1S SFH
Jonathan I Friedman officer: General Counsel DENTSPLY SIRONA INC., 30-30 47TH AVENUE, SUITE 500, LONG ISLAND CITY NY 11101
Lee Rosenthal 10 percent owner C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Quentin S. Blackford director 7475 LUSK BLVD., SAN DIEGO CA 92121
Frank S. Bono officer: Chief Technology Officer 5677 AIRLINE ROAD, ARLINGTON TN 38002
Jason Allan Edie officer: Chief Technology Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Erik E Mickelson officer: Chief Accounting Officer C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Meghan Scanlon director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752